Sanofi India Limited (SANOFI.NS)
INR 6082.6
(-0.65%)
INR 6082.6
(-0.65%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -3.87 Billion INR | 60.51% |
| 2022 | -9.81 Billion INR | 35.16% |
| 2021 | -15.13 Billion INR | -28.82% |
| 2020 | -11.74 Billion INR | -4.9% |
| 2019 | -11.19 Billion INR | -35.73% |
| 2018 | -8.25 Billion INR | -14.36% |
| 2017 | -7.21 Billion INR | -30.94% |
| 2016 | -5.51 Billion INR | 2.38% |
| 2015 | -5.64 Billion INR | -21.48% |
| 2014 | -4.64 Billion INR | -78.82% |
| 2013 | -2.59 Billion INR | 39.28% |
| 2012 | -4.27 Billion INR | -82.66% |
| 2011 | -2.34 Billion INR | 64.26% |
| 2010 | -6.55 Billion INR | -11.84% |
| 2009 | -5.85 Billion INR | -17.81% |
| 2008 | -4.97 Billion INR | -27.33% |
| 2007 | -3.9 Billion INR | -1.17% |
| 2006 | -3.86 Billion INR | -31.16% |
| 2005 | -2.94 Billion INR | -75.96% |
| 2004 | -1.67 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 3.94 Billion INR | 201.81% |
| 2024 Q2 | -2.38 Billion INR | -157.31% |
| 2023 Q3 | 4.48 Billion INR | 208.08% |
| 2023 Q2 | -4.14 Billion INR | -141.26% |
| 2023 FY | -3.87 Billion INR | 60.51% |
| 2023 Q4 | -3.87 Billion INR | -186.48% |
| 2023 Q1 | 10.04 Billion INR | 202.4% |
| 2022 Q3 | 6.99 Billion INR | 205.41% |
| 2022 Q4 | -9.81 Billion INR | -240.39% |
| 2022 FY | -9.81 Billion INR | 35.16% |
| 2022 Q1 | 15.38 Billion INR | 201.63% |
| 2022 Q2 | -6.63 Billion INR | -143.11% |
| 2021 Q4 | -15.13 Billion INR | -261.62% |
| 2021 Q2 | -8.96 Billion INR | -174.9% |
| 2021 FY | -15.13 Billion INR | -28.82% |
| 2021 Q1 | 11.97 Billion INR | 201.92% |
| 2021 Q3 | 9.36 Billion INR | 204.42% |
| 2020 Q4 | -11.74 Billion INR | -169.57% |
| 2020 Q1 | 11.29 Billion INR | 200.86% |
| 2020 Q2 | -16.55 Billion INR | -246.53% |
| 2020 FY | -11.74 Billion INR | -4.9% |
| 2020 Q3 | 16.88 Billion INR | 202.04% |
| 2019 Q2 | -8.23 Billion INR | -199.85% |
| 2019 FY | -11.19 Billion INR | -35.73% |
| 2019 Q3 | 8.3 Billion INR | 200.83% |
| 2019 Q4 | -11.19 Billion INR | -234.81% |
| 2019 Q1 | 8.25 Billion INR | 200.0% |
| 2018 FY | -8.25 Billion INR | -14.36% |
| 2018 Q2 | -7.01 Billion INR | -197.28% |
| 2018 Q1 | 7.21 Billion INR | 200.0% |
| 2018 Q4 | -8.25 Billion INR | -216.15% |
| 2018 Q3 | 7.1 Billion INR | 201.21% |
| 2017 Q4 | -7.21 Billion INR | -204.85% |
| 2017 FY | -7.21 Billion INR | -30.94% |
| 2017 Q3 | 6.88 Billion INR | 201.76% |
| 2017 Q2 | -6.76 Billion INR | -221.07% |
| 2017 Q1 | 5.58 Billion INR | 201.36% |
| 2016 Q4 | -5.51 Billion INR | -192.42% |
| 2016 FY | -5.51 Billion INR | 2.38% |
| 2016 Q1 | 5.71 Billion INR | 200.99% |
| 2016 Q2 | -5.96 Billion INR | -204.32% |
| 2016 Q3 | 5.96 Billion INR | 200.0% |
| 2015 Q1 | 4.68 Billion INR | 200.91% |
| 2015 Q4 | -5.65 Billion INR | -270.97% |
| 2015 Q3 | 3.31 Billion INR | 200.0% |
| 2015 Q2 | -3.31 Billion INR | -170.6% |
| 2015 FY | -5.64 Billion INR | -21.48% |
| 2014 Q3 | 2.87 Billion INR | 200.0% |
| 2014 Q2 | -2.87 Billion INR | -208.77% |
| 2014 Q1 | 2.64 Billion INR | 201.77% |
| 2014 FY | -4.64 Billion INR | -78.82% |
| 2014 Q4 | -4.64 Billion INR | -261.54% |
| 2013 Q2 | -1.57 Billion INR | -136.68% |
| 2013 Q3 | 1.57 Billion INR | 200.0% |
| 2013 FY | -2.59 Billion INR | 39.28% |
| 2013 Q1 | 4.28 Billion INR | 200.23% |
| 2013 Q4 | -2.59 Billion INR | -265.17% |
| 2012 Q3 | - INR | 100.0% |
| 2012 FY | -4.27 Billion INR | -82.66% |
| 2012 Q4 | -4.27 Billion INR | 0.0% |
| 2012 Q2 | -2.34 Billion INR | 0.0% |
| 2011 FY | -2.34 Billion INR | 64.26% |
| 2011 Q4 | -2.34 Billion INR | 0.0% |
| 2010 FY | -6.55 Billion INR | -11.84% |
| 2009 FY | -5.85 Billion INR | -17.81% |
| 2008 FY | -4.97 Billion INR | -27.33% |
| 2007 FY | -3.9 Billion INR | -1.17% |
| 2006 FY | -3.86 Billion INR | -31.16% |
| 2005 FY | -2.94 Billion INR | -75.96% |
| 2004 FY | -1.67 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Abbott India Limited | -20.51 Billion INR | 81.109% |
| Cipla Limited | -3.15 Billion INR | -22.798% |
| Gland Pharma Limited | -14.67 Billion INR | 73.59% |
| GlaxoSmithKline Pharmaceuticals Limited | -674.11 Million INR | -474.832% |
| Kopran Limited | 850.3 Million INR | 555.72% |
| Marksans Pharma Limited | -4.29 Billion INR | 9.782% |
| NGL Fine-Chem Limited | 307.22 Million INR | 1361.295% |
| Pfizer Limited | -19.52 Billion INR | 80.15% |
| SMS Pharmaceuticals Limited | 2.44 Billion INR | 258.443% |
| TTK Healthcare Limited | -7.52 Billion INR | 48.48% |